2. Immunology/Inflammation
  3. CD47
  4. Peluntamig

Peluntamig  (Synonyms: PT-217)

Cat. No.: HY-P991016 Purity: 99.9%
COA
SDS
Technical Support

Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia.

For research use only. We do not sell to patients.

CAS No. : 2928515-21-1

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Peluntamig Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

CD47 & DLL3
In Vivo

Peluntamig (15 mg/kg; i.p.; single injection) combined with cyclophosphamide and 5-fluorouracil (HY-90006) produces a highly significant enhancement in % ILS and a 70% cure rate in BDF1 mice with advanced L1210 leukemia[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 × DBA/2 F1 (BDF1) (male, injected intraperitoneally with 106 L1210 leukemia cells on day 0)[2]
Dosage: 15 mg/kg
Administration: i.p.; single injection; day 3 post-tumor cell inoculation
Result: Produced a percent increase in life span (% ILS) that contributed to an additive predicted % ILS for the triple combination (Peluntamig+cyclophosphamide + 5-fluorouracil).
Yielded an observed % ILS significantly exceeding the additive predicted value (p < 0.001) when used in the triple combination.
Resulted in 7 cures (≥60-day survival) out of 10 treated mice in the triple combination.
Caused a +2% mean weight change 5 days post-treatment when administered alone.
Caused a -9% mean weight change 5 days post-treatment in the triple combination.
Led to no toxic deaths in any treatment group.
Clinical Trial
Gene ID

16423  [NCBI] & 10683  [NCBI]

Accession

Q61735-1 & Q9NYJ7
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Peluntamig]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgG1-kappa
Biological Activity
  • Immobilized Delta-like protein 3/DLL3 Protein, Human (HEK293, His, HY-P700456) can bind Peluntamig. The EC50 for this effect is 19.78 ng/mL.
  • Immobilized CD47 Protein, Human (HEK293, His, HY-P7336) can bind Peluntamig. The EC50 for this effect is 187.6 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Peluntamig Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Peluntamig2928515-21-1PT-217PT217PT 217CD47Cluster of Differentiation 47MER6OA3small cell lung cancer tumor cellsNK-cell-mediated cytotoxicityL1210 leukemiacyclophosphamideBDF 1 mice5-fluorouracilDLL3macrophage phagocytosismouse models
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Peluntamig
Cat. No.:
HY-P991016
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.